Although BRAF inhibitors inhibit the MEK/ERK pathway in melanoma with the BRAFV600E mutation, it has been reported that a paradoxical activation of the MAPK pathway in BRAF wild‐type cells is linked to the adverse actions of vemurafenib [25, 26, 27]. The gene discussed is BRAF; the disease is melanoma.